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Giovanna Zambruno6, Leila Youssefian7, Hassan Vahidnezhad8,9, Luis Requena2, Peter Itin10, Gianluca Tadini11,
Ivelina Yordanova12, Ludovic Martin13, Jouni Uitto8, Cristina Has14 and Marcela Del Rio1,2,3,4
Abstract
Background: Kindler Syndrome (KS) is a rare genodermatosis characterized by skin fragility, skin atrophy, premature
aging and poikiloderma. It is caused by mutations in the FERMT1 gene, which encodes kindlin-1, a protein involved
in integrin signalling and the formation of focal adhesions. Several reports have shown the presence of non-
melanoma skin cancers in KS patients but a systematic study evaluating the risk of these tumors at different ages
and their potential outcome has not yet been published. We have here addressed this condition in a retrospective
study of 91 adult KS patients, characterizing frequency, metastatic potential and body distribution of squamous cell
carcinoma (SCC) in these patients. SCC developed in 13 of the 91 patients.
Results: The youngest case arose in a 29-year-old patient; however, the cumulative risk of SCC increased to 66.7%
in patients over 60 years of age. The highly aggressive nature of SCCs in KS was confirmed showing that 53.8% of
the patients bearing SCCs develop metastatic disease. Our data also showed there are no specific mutations that
correlate directly with the development of SCC; however, the mutational distribution along the gene appears to be
different in patients bearing SCC from SCC-free patients. The body distribution of the tumor appearance was also
unique and different from other bullous diseases, being concentrated in the hands and around the oral cavity,
which are areas of high inflammation in this disease.
Conclusions: This study characterizes SCCs in the largest series of KS patients reported so far, showing the high
frequency and aggressiveness of these tumors. It also describes their particular body distribution and their
relationship with mutations in the FERMT-1 gene. These data reinforce the need for close monitoring of
premalignant or malignant lesions in KS patients.
Keywords: Kindler syndrome, SCC, Skin cancer, Bullous disease, Prevalence
Background
Kindler Syndrome (KS) is a rare autosomal recessive
genodermatosis, considered a subtype of epidermolysis
bullosa (EB), characterized by skin fragility with
photosensitivity and acral blisters formation in young
patients [1]. As they age, they develop progressive skin
atrophy, premature aging, poikiloderma, palmoplantar
hyperkeratosis, and pseudosyndactyly [2]. Mucosal mani-
festations are also common and include haemorrhagic
mucositis and gingivitis, periodontal disease, premature
loss of teeth, and labial leukokeratosis [3]. Interestingly,
unlike other skin bullous diseases, KS is characterized by
sensitivity to UV and dysregulation of oxidative stress
[4], [5], [6].
KS is caused by mutations in the FERMT1, a gene that
codes for kindlin-1, a protein associated to integrin and
focal adhesions [7], [8].
Reports in the literature have documented the pres-
ence of SCCs in KS patients suggesting a predisposition
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of these patients to this neoplasia [9], [10]. However, a
systematic study of cancer frequency and aggressiveness
in a series of KS patients has not been carried out.
Therefore, the relative risk of SCC at different ages can-
not be predicted from the current published data on KS.
Furthermore, although SCCs in KS have been described
in individual case reports, published studies do no pro-
vide common behaviours, body location and the exist-
ence or lack of mutations in FERMT1 that can be
directly associated with cancer in KS.
We have previously reported the largest series of KS
patients from different countries and with the associated
FERMT 1 (KIND1) genotype in patients of different eth-
nicities. The development of cutaneous cancer was
noted in some patients; however, tumor characteristics
and follow-up data were not provided [2].
In this paper we present a series of 91 cases, 69 cases
previously published [2], [11] and 22 new cases unpub-
lished, with the primary goal of establishing the inci-
dence of SCC in KS patients, at different ages. We have
also used this series, in some cases supplemented with
data from the literature, to investigate other characteris-
tics of SCCs in KS, such as tumoral prognosis and out-
come, body distribution of the tumors and the existence
or lack of KS mutations associated to SCC appearance.
To our knowledge, this represents the first study pub-
lished that characterizes as a whole, SCC in Kindler
syndrome.
Results
Patients and development of SCC
Information about our patients including gender, age,
genetic data and the presence of muco-cutaneous SCC
is provided (Table 1).
In our series of 91 patients, 13 developed non-
melanoma skin tumors. Most of these patients presented
multiple tumors, which resulted in a total of 25 tumors
in the skin and 2 in the oral mucosa. With the exception
of one BCC, all of the neoplastic lesions were SCC of
variable histological grades but mostly well differentiated
SCC.
When the patients were stratified by age, and the cu-
mulative incidence calculated, our data showed that the
earliest SCC appeared in a 29 year old woman and the
cumulative risk of SCC increased with age to reach
66.7% in patients over 60 years of age.
The SCC development cumulative risk in KS was com-
pared to that reported for other types of EB patients and
spontaneous SCC (Fig. 1). The KS profile is different
from recessive dystrophic EB (RDEB) in which SCCs de-
velop earlier and reach a higher cumulative risk and are
also different from the generalized non-Herlitz types of
Junctional EB (JEB) patients profile [28], [29], which
showed a lower incidence and later onset. Fig. 1 shows
the data from Fine et al., although this data has been
somewhat controversial [29], [30]. Furthermore, in a
series of one of our authors, the frequency appears much
lower with only 1 SCC in 70 patients with Collagen XVII
mutation and none in patients with Laminin322 or In-
tegrin α6β4 mutations (Has, C. et al. unpublished re-
sults). In contrast, the incidence of sporadic SCC of sun
exposed areas in the general population was much lower
(0.001–0.005%), even in older patients (Fig. 1) [31], [26].
The outcome of SCCs (Table 1) in these patients has
been variable leading to premature demise in five pa-
tients and arm amputation in another. Overall, 53.8% (7/
13 cases) of the patients with SCC present metastasis .
Regarding mortality, 5/13 KS patients (38.5%), that de-
veloped SCC died as a direct consequence of the tumor,
in a period that varied between 2 and 7 years, with an
average of 40.8 months. This percentage(50%) is consist-
ent with the previously reported data for KS-SCC [11],
but much higher than the 5–10% of mortality described
for sporadic tumors [31], [26]. Their detailed demo-
graphic, clinical and histopathological features are pre-
sented in Table 2.
The information in Table 2, includes grading of KS-SCC
in 26/37 tumors (17/22 KS patients with histological data
available). SCC considered as well-differentiated forms
were the majority of the cases (22/26: 84.6%), moderately
to poorly differentiated SCCs, were only presented in 4/26
(15.38%).
In order to study gender influence on the development
of the KS-SCC, Table 3 was expanded to include previ-
ously published studies as well as the patients in this
study. Our analysis did not reveal a significant difference
in the development of SCC in male and female KS pa-
tients (Table 3).
Even though a difference in the total number of tu-
mors in men and women cannot be observed, there
seems to be a tendency in women to develop tumors at
earlier ages (4/9: 44% before the 40’s), whereas in men,
there was an abrupt increase after 40 years of age (10/13:
77%).
Location of tumors
The location of the tumors in the body is shown (Fig. 2).
All the KS-SCC described in the literature were also in-
cluded in the figure [11], thus, a total of 37 SCC was
used for this analysis. Furthermore, when tumors of this
study and tumors from the literature were segregated,
results were nearly identical (data not shown).
It can be observed that the majority of the tumors (28/
37) developed in sun exposed areas, with the exception
of 6 SCC of the oral mucosa, foot and penis, with 3 of
them in moderately sun exposed areas (Fig. 2a). Surpris-
ingly, most tumors were restricted to just two areas of
the body; the face, particularly around the mouth (13/37
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tumors), and hands (16/37 tumors); that together repre-
sented 78% of the KS-SCCs. Other sun-exposed areas
were minimally affected, which resulted in a unique
distribution, that overlaps with areas of chronic
inflammation in KS patients [42], [43]. This pattern is
different from sporadic [26] JEB [29] and RDEB associ-
ated SCCs [44].
The body distribution of SCC was represented with a
key color. These classified every tumor if the zone was
considered as a sun exposed area (Fig. 2a) and if the
zone had been described as chronically inflamed in KS
(Fig. 2b). It can be observed that, in KS-SCC there is a
perfect coincidence between areas of chronic inflamma-
tion and tumor development.
Mutations in SCC bearing KS patients
In order to discern if the predisposition to develop SCC
was related with a pattern in the mutational spectra,
gDNA mutations were represented (Fig. 3). In our series
of KS patients, no hot spot, at genomic level, associated to
SCC development was identified. Our data showed that
SCC developed in patients with 10 different FERMT1 mu-
tations. In most cases, there was one patient with SCC, for
each mutation, with the exception of two mutations
present in multiple patients. Three patients with the mu-
tations c.328C > T (p.R110X; g.6115868G > A) developed a
total of 5 tumors and 2 patients with the mutation c.958-
1G >A (altered splicing in intron 7; g.6097034C > T)
developed 7 tumors. Thus, these two mutations were
characterized not only for the higher frequency of patients
with SCC, but also for a higher multiplicity of tumors.
Another interesting mutation was c.96-97delAG
(p.R32SfsX63 g.6119458-6119459delCT) presented in a
single SCC bearing KS patient, while all other mutations
in patients with SCC were also presented in patients free
of neoplasia. We have represented the mutations for all
our 91 case series (only 87 with mutational information
available) for those who are free of neoplasias and those
that developed SCC (Fig. 3). When we compared the spec-
tra of mutations of patient bearing tumors with the tumor
free patients we found an interesting pattern.
From our data (Fig. 3 and Table 1), we can see that 10
out of 13 KS patients that developed SCCs, presented mu-
tations that resulted in stop codons being located closer to
the 5’end of FERMT1, which resulted in short transcripts
that were likely to be degraded. The other three mutations
were also frame shifts or alternative splicing which are
likely to generate an unstable protein. In contrast, the
spectra of mutations reported in the literature, in patients
with and without tumors, showed a more even distribu-
tion all along the gene and with a higher representation at
the sequence encoding carboxy terminus. In addition, ac-
cording to the literature, non-sense mutations represent
37.5% of the total KS mutations [2] which is consistent
with our study (36.6%). In patients with SCC, this propor-
tion increases up to 60% (6 out of 10 reported mutations).
Taking together all of this data, suggests than even though
specific mutations do not have a predictive value in the
development of SCC, there is a different profile of muta-
tions in patients bearing tumors and tumor free patients.
Discussion
In a case series of 91 KS patients, we have determined
that KS patients have a high risk for developing SCC.
The data from our case series indicated that SCCs ap-
peared relatively early compared with sporadic SCC, but
occurred about 10 to 20 years later than in RDEB, which
is the type of EB with the highest risk of cancer [28]. On
Fig. 1 Calculated cumulative risk of the first squamous cell carcinoma in Kindler syndrome patients. For comparative purposes, we have also
plotted the calculated cumulative risk described for RDEB, JEB and the general population which were taken from the literature [26], [27]
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the other hand, SCC in JEB showed a higher latency and
a lower incidence than KS.
The youngest patient that developed SCC in our
series was a 29 year old female. It is worth noting
that consistent with our study, there are only three
younger KS patients of 16, 23 and 27 described with
SCC in the literature [32], [33], [34]. It can be in-
ferred that development of SCC in young patients is
rare and in the case of paediatric patients is ex-
tremely rare or non-existent.
The cumulative incidence of SCC in KS increases after
the early onset at 29 years old, to reach a maximum at
60 years old with a cumulative risk of 67%.
Of note, the body localization of cutaneous cancers in
KS is also unique. Unlike RDEB and JEB, in which, the
preponderance of lesions in the lower extremities is
clear, KS tumors arose mainly in the mouth and hands.
Interestingly, KS has been shown to have an oversensi-
tivity to UV, but other areas of the body, highly exposed
to the sun, were minimally affected [45]. This particular
distribution was confirmed including 9 other KS patients
that developed SCCs which were taken from the litera-
ture. Tumors in non-exposed areas were less common
and were restricted to 6 patients; 4 in the oral mucosa,
one, in the penis and another in the foot. RDEB and JEB
SCCs are associated with chronically non-healing ulcera-
tions, while in KS, the cutaneous condition improves
with age. The adult skin in KS is characterized by atro-
phy, poikiloderma as well as inflammation of the mouth,
hands and feet [42], [41]. These differential distributions
support the notion that distinct pathogenic mechanisms
may underlie cancer development in KS as compared to
the other major EB types. Photosensitivity is a unique
feature of KS among the EB disease spectrum, and loss
of kindlin-1 is associated with an up-regulation of pro-
inflammatory cytokines in keratinocytes, at least in part
mediated by UV exposure with subsequently impaired
DNA repair [4]. Furthermore, in KS we have observed
mitochondrial damage with an increase in oxidative
stress [5]. KS has also been characterized by strong in-
flammation in the mouth and hands [42], [43], [41].
Thus, SCC seems to develop by a synergy of UV expos-
ure together with the stimulus of inflammation, in the
mouth and hands, which results in the peculiar distribu-
tion of these tumors.
Interestingly, as in other EB related cancers, the SCC
of the KS patients has the potential to be highly aggres-
sive [28] leading to amputation [32], [33], [10] and early
demise [32]. In agreement, in our series, five patients
died as a consequence of the tumors, and another
patient showed local metastasis which resulted in an am-
putation of an arm.
The mechanisms involved in the aggressive nature and
early onset of SCC associated with ulcerative disease and
chronic inflammation have not been completely
Fig. 2 Representation of the body distribution of KS-SCCs. a The key color, classifies every tumor in different areas according to its´ UV exposure:
Non-exposed (green), Moderately-exposed (orange) and Highly-exposed (red). b The key color, classifies every tumor in different areas according
to whether the zone has been described as chronically inflamed in KS: no inflammation (green) and chronic inflammation (orange)
Table 3 Gender and age distribution of SCCs appearance in all
the KS patients that has been reported
Patients with carcinoma (including bibliography)
Age range Male Female Total
16–19 1 0 1
20–29 1 2 3
30–39 1 2 3
40–49 6 1 7
50–59 4 3 7
60–69 0 1 1
70–79 0 0 0
Total 13 9 22
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elucidated. The putative role of Kindlin-1 has been widely
discussed by Rognoni et al. (2014) which focused on the
activation of TGF-β–mediated growth-inhibitory signals
in the KS mouse model [46]. Moreover, TFG-beta has
been described as a crucial factor in other bullous diseases
modifying disease severity in RDEB, through the promo-
tion/inhibition of a fibrotic matrix [47]. More recently,
our group has underscored the role of the fibroblasts of
KS, RDEB, and XPC, in the pathogenesis of these diseases,
observing a higher activation of the TGF-β signalling path-
way [48]. Taking together all these data and consistent
with the body distribution described in this study, a poten-
tial mechanistic role of the TGF-β in the aggressive nature
of KS-SCC becomes even more important, and should be
further characterized.
In the last few years, a role of the stroma has been con-
sidered determinant and at least partially responsible for
the early onset and aggressiveness of these tumors [48],
[49], [50]. More recently; however, careful genetic studies
by Cho et al. (2018) have shown that driver mutations
seem to be shared between RDEB and sporadic skin tu-
mors in sun exposed areas and other highly aggressive
SCC, but unlike the sporadic tumor genes, RDEB showed
a profile of endogenous mutations associated with APO-
BEC [51]. The alteration of these genes seems to be
related with inflammation and is probably responsible of
the differences between sporadic tumors and tumors asso-
ciated with chronic ulcerative diseases and inflammation.
Based on this data, we speculate that similar mechanism
may occur in KS, in which tumors appear in areas that are
both exposed to UV and present higher inflammation (i.e.
mouth and hands).
In regard to the nature of FERMT1 mutations in pa-
tients that developed SCC, we showed that there are no
clear hot spots or even predominant mutations in our
cohort. Only two mutations are found in two and three
patients, respectively. Although some mutations appear
in this study more frequently associated with SCC (96,
3731, 22558 and 30534), there is not enough statistical
significance to consider that they have a predictive value.
In addition, none of the mutations seems to be carcino-
genic ¨per se¨ since several mutations are found in
patients bearing cancer and also in patients in which
SCC have not been detected. However, the mutational
distribution in FERMT1 and the type of mutation in the
KS patients with SCC, was clearly different from that of
the patients that did not develop SCC. While mutations
in the overall population are distributed along the whole
length of the gene, the mutations in the patients bearing
SCC are mostly present in the N terminal part of the
gene. Furthermore, most of them result in stop codons,
which lead to short mRNA that are likely to be de-
graded. Taken together, these data suggest that most of
the patients were null for kindlin-1, which is a paradox-
ical result, taking into account that there is a reasonable
body of literature suggesting a pro-carcinogenic role of
this protein. Overexpression of kindlin 1 has been re-
ported in breast, lung, colon and esophageal cancers
[52]. Furthermore, overexpression of this protein has
also been associated with a poor prognosis in osteosar-
coma [53] as well as breast and lung carcinomas and
pancreatic cancer [54]. Based on these results, we
conclude that kindlin1 may have a pro-carcinogenic or
anticarcinogenic potential depending on the context as
Fig. 3 Distribution of the mutations in our patient series, along the gDNA of FERMT1. In the X axis, it is represented by the length of the FERMT1
gene, considering the + 1 position as the ATG. For that reason, the gene is from − 3990 to + 44709 positions. The Y-axis, shows the number of
patients presenting with each mutation, in orange (free of SCC) and in blue (developed SCC). Four patients with no mutational information
available were excluded from this figure
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has been shown in other genes such as E2F, which can
act as a tumor suppressor gene or an oncogene depend-
ing on the context [55].
A limitation of the present study is the relatively low
number of cases, particularly in older patients. However,
since the total population of reported patients with KS is
less than 300, the report of 91 patients can be consid-
ered as a representative sample for such a rare disease.
Similarly, in ideal circumstances, the risk of a disease
should be assessed in a more homogeneous population.
Our series included people from different countries and
ethnicities. However, given the low prevalence of this
disease, it would be impossible to do a study of these
characteristics in a homogeneous population. Further-
more, our study analyzed 26 carcinomas in 13 different
patients being so far 19, the total number of KS-SCC
previously reported in the literature [11].
Conclusions
Overall, this study predicts that more than half of pa-
tients with KS will develop SCC in their lifetime and
among them, 53.8% of patients will develop metastatic
disease with a high possibility of a lethal outcome. Thus,
it is important to stress the need for close monitoring of
these patients, aiming at early SCC detection (at pre-
malignant stages and/or initial developmental stages) to
avoid progression of the tumor, particularly in older pa-
tients when the symptoms of the disease are less severe
and therefore, the monitoring may be less strict.
Methods
Patients and tumors
Patients for this retrospective study were recruited from
different institutions in Europe and the United States.
The core of our series are 34 patients previously de-
scribed by Has et al. [2] to which, we included 57 new
patients who were diagnosed with KS by clinical and
molecular methods and who had records of tumor de-
velopment as well as their characteristics [19]; [14]; [15].
All the patients included in this study were older than
16 years, the age of the youngest KS patient who devel-
oped a SCC [32]. In four patients from our series,
FERMT1 mutations were not available and therefore,
these patients were not included in the mutational distri-
bution study (Fig. 3).
This series of 91 patients was used primarily to deter-
mine the incidence of SCC in KS, which has not been
previously reported. In order to investigate other charac-
teristics of KS-SCC, we have supplemented the informa-
tion of our series with data from the literature.
For the SCC body distribution study, we have used 37
tumors, coming from 13 patients of our series and 9
additional KS patients from the literature [11]. To our
knowledge, all the tumors and information available
reported until now, are included here. Information re-
garding pedigree was not available for this study. To
summarize, different groups of patients have been in-
cluded in each analysis depending on the information
available from them (mutations, follow up, histopatho-
logical characterization of the tumors,…). For cumulative
risk calculation, 91 KS patients have been included (13
of which developed SCC) as was mentioned before and
are shown in Table 1. For mutation distribution analysis
(Fig. 3), only 87 KS patients were included from our 91
patients series, because 4 patients have no mutational in-
formation available (Patients #12, 41, 57 and 72 from
Table 1). The SCC body distribution analysis shown in
Fig. 2 was analyzed in 22 KS patients (from the bibliog-
raphy and from our series) who developed a total of 37
tumors. The same group of patients was used to elabor-
ate Table 2 that describes all the SCC bearing patients,
but only 26/37 tumors had complete histopathological
data available. For gender and age distribution analysis
(Table 3), the same group of 22 SCC-KS patients was
studied.
Distribution of mutations along the FERMT1 gene
The position of the mutations (Table 1 and Fig. 3) are
expressed in both c.DNA and g.DNA. For cDNA number-
ing, + 1 corresponds to the A of the ATG translation
initiation codon in the reference sequence. cDNA varia-
tions in nucleotides are in accordance with GenBank entry
NM_017671.4, while g.DNA positions were calculated
from those using the position converter available in the
web-based software Mutalyzer (build hg38, www.mutaly-
zer.nl) [56]. If only one mutation is mentioned, then it is
in a homozygous state. The mapping along protein do-
mains was not performed because most of the mutations
are stop codons and likely to degrade the mRNA.
Statistical analysis
Cumulative risk was obtained by calculating the number
of new cases over the population at risk for each age
segment. To compare the distribution of the mutations
along the FERMT1 gene, parametric and non-parametric
tests (Chi square, q-q test, ANOVA and Kruskal-Wallis
test) were performed using R package v.3.1.2. Differences
between groups were considered significant at P < 0.05.
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